Holen Sie sich die Stockscreener-App
216.63
0.28%
0.60
Handel nachbörslich:
217.00
0.37
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$216.03
Offen:
$215.74
24-Stunden-Volumen:
1.24M
Relative Volume:
1.03
Marktkapitalisierung:
$31.98B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
23.25
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+8.47%
1M Leistung:
+10.53%
6M Leistung:
+22.51%
1J Leistung:
+71.82%
1-Tages-Spanne:
$214.08
$219.72
1-Wochen-Bereich:
$197.01
$219.72
52-Wochen-Spanne:
$121.05
$219.72
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
216.63 | 31.89B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,229.93 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.51 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.31 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.38 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.59 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Defensive Index - marketscreener.com
Biogen: Key Takeaways From Needham’s Meeting With Top Management - Benzinga
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB - GlobeNewswire Inc.
Biogen to present Alzheimer’s drug data at upcoming conference - Investing.com
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen - Biogen
Biogen to Highlight Breadth of Alzheimer’s Disease - GlobeNewswire
BIIB Maintained by Needham -- Price Target Raised to $256 - GuruFocus
The Vumerity from Biogen Inc.oral MS therapy with a quieter side-effect profile - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen WinHas The Bull Case Changed? - simplywall.st
Biogen shares at a four month high, analysts still watch BIIB - Ad-hoc-news.de
Biogen clears a fresh 52-week high, shares react to RayThera deal and FDA tag - Ad-hoc-news.de
Enterprise value to revenue forward of Biogen Inc. – MUN:IDP - TradingView
Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs - simplywall.st
Biogen Inc (BIIB) Shares Surge 7.0% -- What GF Score of 74 Tells Investors - GuruFocus
Why Biogen (BIIB) Stock Is Up Today - Yahoo Finance
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - Reuters
symbol__ Stock Quote Price and Forecast - CNN
Biogen Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump? - Yahoo Finance
Biogen reaches fresh 52-week high, shares extend strong S&P 500 run - Ad-hoc-news.de
Enterprise value to EBIT forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Biogen Inc. – HAM:IDP - TradingView
Biogen marks a fresh 52-week high, shares extend NASDAQ biotech rally - Ad-hoc-news.de
Biogen stock reaches 52-week high at 206.21 USD By Investing.com - Investing.com South Africa
Biogen stock reaches 52-week high at 206.21 USD - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Price to sales forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation - simplywall.st
Enterprise value to EBITDA forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Price to book forward of Biogen Inc. – TURQUOISE:BIIBN - TradingView
Biogen Expands Spinraza Patent Fight With Cipla, Somerset Suits - Bloomberg Law News
Biogen updates Alzheimer’s pipeline plans, shares on Nasdaq in focus - Ad-hoc-news.de
Law firm investigates Biogen for possible securities fraud after study misses key endpoint, stock drops 6.4%. - Pluang
Biogen to Acquire RayThera for Up to $1 Billion - Global Legal Chronicle
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Omada Health, Inc. (OMDA) - The Globe and Mail
WilmerHale Advises Biogen in Acquisition of RayThera - WilmerHale
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook - Investing.com
Biogen to acquire RayThera for USD 1B - Medical Buyer
Biogen Inc. (BIIB) Investor Outlook: Evaluating the Potential 12% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biogen Inc. (BIIB) And Encourages Shareholders to Reach Out - ACCESS Newswire
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Biogen acquires RayThera in deal worth up to $1 billion - qz.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):